VTGN logo

VistaGen Therapeutics (VTGN) Selling, General & Administrative Expenses

Annual SG&A

$14.06 M
-$601.00 K-4.10%

31 March 2024

1-Year Change

-4.1%
VTGN annual selling, general & administrative expenses is down -4.1% year-on-year

3-Year Change

+98.13%
VTGN annual selling, general & administrative expenses is up +98.13% over the past 3 years

All-time High

$14.66 M
VTGN annual selling, general & administrative expenses is currently -4.10% below its historical high of $14.66 million

Sector Rank

30.85%
VTGN annual selling, general & administrative expenses is higher than 30.85% of companies in Healthcare sector
Annual Total Expenses$34.09 M
VTGN annual total expenses is $34.09 million
Annual Operating Expenses$34.09 M
VTGN annual total operating expenses is $34.09 million
Annual Revenue$1.06 M
VTGN annual revenue is $1.06 million
Annual Net Income-$29.36 M
VTGN annual net profit is -$29.36 million

VTGN Selling, General & Administrative Expenses Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly SG&A

$4.20 M
-$372.00 K-8.15%

30 September 2024

1-Year Change

+11.63%
VTGN quarterly selling, general & administrative expenses is up +11.63% year-on-year

3-Year Change

+34.54%
VTGN quarterly selling, general & administrative expenses is up +34.54% over the past 3 years

All-time High

$7.83 M
VTGN quarterly selling, general & administrative expenses is currently -46.42% below its historical high of $7.83 million

Sector Rank

33.68%
VTGN quarterly selling, general & administrative expenses is higher than 33.68% of companies in Healthcare sector
Quarterly Total Expenses$14.41 M
VTGN quarterly total expenses is $14.41 million
Quarterly Operating Expenses$14.41 M
VTGN quarterly total operating expenses is $14.41 million
Quarterly Revenue$183.00 K
VTGN quarterly revenue is $183.00 thousand
Quarterly Net Income-$12.96 M
VTGN quarterly net profit is -$12.96 million

VTGN Quarterly SG&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM SG&A

-$1.45 B
-$39.57 M-2.81%

30 September 2024

1-Year Change

-11234.02%
VTGN TTM selling, general & administrative expenses is down -11234.02% year-on-year

3-Year Change

-13195.13%
VTGN TTM selling, general & administrative expenses is down -13195.13% over the past 3 years

All-time High

$16.64 M
VTGN TTM selling, general & administrative expenses is currently -8812.51% below its historical high of $16.64 million

Sector Rank

34.84%
VTGN TTM selling, general & administrative expenses is higher than 34.84% of companies in Healthcare sector
Annual Total Expenses$34.09 M
VTGN annual total expenses is $34.09 million
Annual Operating Expenses$34.09 M
VTGN annual total operating expenses is $34.09 million
TTM Revenue$875.70 K
VTGN TTM revenue is $875.70 thousand
TTM Net Income-$39.57 M
VTGN TTM net profit is -$39.57 million

VTGN TTM SG&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

VTGN Selling, General & Administrative Expenses Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-4.1%+11.6%-10000.0%
3 y3 years+98.1%+34.5%-10000.0%
5 y5 years+89.2%+97.8%-10000.0%

VTGN Selling, General & Administrative Expenses High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-4.1%+98.1%-12.5%+40.9%-54.4%at low
5 y5 years-4.1%+113.1%-12.5%+230.3%-90.8%at low
alltimeall time-4.1%>+9999.0%-46.4%>+9999.0%<-9999.0%at low

VistaGen Therapeutics Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sept 2024
-
$4.20 M(-8.1%)
$16.64 M(+6.3%)
June 2024
-
$4.57 M(+10.8%)
$15.65 M(+11.3%)
Mar 2024
$14.06 M(-4.1%)
$4.12 M(+9.6%)
$14.06 M(+8.0%)
Dec 2023
-
$3.76 M(+17.2%)
$13.02 M(+5.4%)
Sept 2023
-
$3.21 M(+7.7%)
$12.36 M(-3.9%)
June 2023
-
$2.98 M(-3.2%)
$12.85 M(-12.4%)
Mar 2023
$14.66 M(+10.7%)
$3.08 M(-0.5%)
$14.66 M(-8.8%)
Dec 2022
-
$3.09 M(-16.5%)
$16.08 M(-0.2%)
Sept 2022
-
$3.70 M(-22.7%)
$16.11 M(+3.1%)
June 2022
-
$4.79 M(+6.5%)
$15.63 M(+18.0%)
Mar 2022
$13.25 M(+86.6%)
$4.50 M(+44.3%)
$13.25 M(+19.7%)
Dec 2021
-
$3.12 M(-3.2%)
$11.07 M(+9.9%)
Sept 2021
-
$3.22 M(+33.6%)
$10.07 M(+24.0%)
June 2021
-
$2.41 M(+3.9%)
$8.12 M(+14.4%)
Mar 2021
$7.10 M(+7.5%)
$2.32 M(+9.6%)
$7.10 M(+14.5%)
Dec 2020
-
$2.12 M(+66.7%)
$6.20 M(-0.1%)
Sept 2020
-
$1.27 M(-8.7%)
$6.21 M(+2.0%)
June 2020
-
$1.39 M(-2.2%)
$6.08 M(-7.9%)
Mar 2020
$6.60 M(-11.2%)
$1.42 M(-32.9%)
$6.60 M(-7.6%)
Dec 2019
-
$2.12 M(+85.1%)
$7.14 M(+4.2%)
Sept 2019
-
$1.15 M(-40.0%)
$6.85 M(-13.0%)
June 2019
-
$1.91 M(-2.7%)
$7.88 M(+6.0%)
Mar 2019
$7.43 M(+21.0%)
$1.96 M(+7.3%)
$7.43 M(-9.7%)
Dec 2018
-
$1.83 M(-15.7%)
$8.23 M(+11.4%)
Sept 2018
-
$2.17 M(+48.1%)
$7.39 M(-1.5%)
June 2018
-
$1.47 M(-46.9%)
$7.50 M(+4.2%)
Mar 2018
$6.14 M(+4.7%)
$2.76 M(+179.5%)
$7.20 M(+23.6%)
Dec 2017
-
$988.30 K(-56.8%)
$5.83 M(-13.6%)
Sept 2017
-
$2.29 M(+96.3%)
$6.75 M(+13.6%)
June 2017
-
$1.17 M(-16.0%)
$5.93 M(+1.1%)
Mar 2017
$5.87 M(-25.1%)
$1.39 M(-27.2%)
$5.87 M(-52.3%)
Dec 2016
-
$1.91 M(+29.0%)
$12.31 M(+4.9%)
Sept 2016
-
$1.48 M(+34.5%)
$11.74 M(-16.1%)
June 2016
-
$1.10 M(-86.0%)
$13.99 M(-1.6%)
DateAnnualQuarterlyTTM
Mar 2016
$7.84 M(+80.4%)
$7.83 M(+486.3%)
$14.22 M(+63.2%)
Dec 2015
-
$1.34 M(-64.2%)
$8.71 M(+8.3%)
Sept 2015
-
$3.73 M(+181.4%)
$8.05 M(+65.1%)
June 2015
-
$1.33 M(-42.9%)
$4.87 M(+12.2%)
Mar 2015
$4.34 M(+85.4%)
$2.32 M(+245.8%)
$4.34 M(+74.3%)
Dec 2014
-
$671.00 K(+20.7%)
$2.49 M(-0.8%)
Sept 2014
-
$556.00 K(-30.2%)
$2.51 M(+0.4%)
June 2014
-
$797.00 K(+69.9%)
$2.50 M(+6.7%)
Mar 2014
$2.34 M(-34.2%)
$469.00 K(-32.0%)
$2.34 M(-32.0%)
Dec 2013
-
$690.00 K(+26.6%)
$3.45 M(-3.1%)
Sept 2013
-
$545.00 K(-14.7%)
$3.56 M(-0.8%)
June 2013
-
$639.00 K(-59.4%)
$3.58 M(+0.6%)
Mar 2013
$3.56 M(-18.2%)
$1.57 M(+96.8%)
$3.56 M(+4.2%)
Dec 2012
-
$799.00 K(+39.7%)
$3.42 M(-3.1%)
Sept 2012
-
$572.00 K(-7.6%)
$3.53 M(-8.4%)
June 2012
-
$619.00 K(-56.7%)
$3.85 M(-11.7%)
Mar 2012
$4.36 M(>+9900.0%)
$1.43 M(+57.4%)
$4.36 M(+48.5%)
Dec 2011
-
$907.00 K(+1.4%)
$2.93 M(+44.6%)
Sept 2011
-
$894.60 K(-20.6%)
$2.03 M(+78.6%)
June 2011
-
$1.13 M(>+9900.0%)
$1.14 M(>+9900.0%)
Mar 2011
-
$5200.00(+188.9%)
$11.00 K(+29.4%)
Dec 2010
$8500.00(-60.5%)
$1800.00(-10.0%)
$8500.00(+6.3%)
Sept 2010
-
$2000.00(0.0%)
$8000.00(+11.1%)
June 2010
-
$2000.00(-25.9%)
$7200.00(0.0%)
Mar 2010
-
$2700.00(+107.7%)
$7200.00(-66.7%)
Dec 2009
$21.50 K(+31.9%)
$1300.00(+8.3%)
$21.60 K(-34.9%)
Sept 2009
-
$1200.00(-40.0%)
$33.20 K(+3.4%)
June 2009
-
$2000.00(-88.3%)
$32.10 K(+2.9%)
Mar 2009
-
$17.10 K(+32.6%)
$31.20 K(+91.4%)
Dec 2008
$16.30 K
$12.90 K(>+9900.0%)
$16.30 K(+379.4%)
Sept 2008
-
$100.00(-90.9%)
$3400.00(+3.0%)
June 2008
-
$1100.00(-50.0%)
$3300.00(-26.7%)
Mar 2008
-
$2200.00(-4.3%)
$4500.00(0.0%)
June 2007
-
$2300.00(+4.5%)
$4500.00(+104.5%)
Mar 2007
-
$2200.00
$2200.00

FAQ

  • What is VistaGen Therapeutics annual selling, general & administrative expenses?
  • What is the all time high annual SG&A for VistaGen Therapeutics?
  • What is VistaGen Therapeutics annual SG&A year-on-year change?
  • What is VistaGen Therapeutics quarterly selling, general & administrative expenses?
  • What is the all time high quarterly SG&A for VistaGen Therapeutics?
  • What is VistaGen Therapeutics quarterly SG&A year-on-year change?
  • What is VistaGen Therapeutics TTM selling, general & administrative expenses?
  • What is the all time high TTM SG&A for VistaGen Therapeutics?
  • What is VistaGen Therapeutics TTM SG&A year-on-year change?

What is VistaGen Therapeutics annual selling, general & administrative expenses?

The current annual SG&A of VTGN is $14.06 M

What is the all time high annual SG&A for VistaGen Therapeutics?

VistaGen Therapeutics all-time high annual selling, general & administrative expenses is $14.66 M

What is VistaGen Therapeutics annual SG&A year-on-year change?

Over the past year, VTGN annual selling, general & administrative expenses has changed by -$601.00 K (-4.10%)

What is VistaGen Therapeutics quarterly selling, general & administrative expenses?

The current quarterly SG&A of VTGN is $4.20 M

What is the all time high quarterly SG&A for VistaGen Therapeutics?

VistaGen Therapeutics all-time high quarterly selling, general & administrative expenses is $7.83 M

What is VistaGen Therapeutics quarterly SG&A year-on-year change?

Over the past year, VTGN quarterly selling, general & administrative expenses has changed by +$437.00 K (+11.63%)

What is VistaGen Therapeutics TTM selling, general & administrative expenses?

The current TTM SG&A of VTGN is -$1.45 B

What is the all time high TTM SG&A for VistaGen Therapeutics?

VistaGen Therapeutics all-time high TTM selling, general & administrative expenses is $16.64 M

What is VistaGen Therapeutics TTM SG&A year-on-year change?

Over the past year, VTGN TTM selling, general & administrative expenses has changed by -$1.46 B (-11234.02%)